Biogen's Revenue Decline in 2025: A Cautionary Tale for Investors

Biogen Inc. (NASDAQ: BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17% year-over-year (YoY), beating the consensus estimate of $3.35. Revenue of $2.46 billion, up 3% YoY, also surpassed the consensus of $2.40 billion. However, the company's outlook for 2025 raised concerns, as it expects a full-year adjusted EPS of $15.25-$16.25, below the consensus of $16.34, and a mid-single-digit percentage decline in revenue. The stock price dropped 6.74% to $130.00 following the announcement.

The company's multiple sclerosis (MS) franchise, a significant revenue driver, is facing increased competition, leading to a decline in sales. In the fourth quarter, MS revenue decreased by 8% YoY, with Tysabri sales down to $415.4 million from $464.7 million. Additionally, contract manufacturing revenue declined by $247 million, contributing to the overall revenue decrease.

Biogen's recent product launches, such as Leqembi and Skyclarys, have shown promise but face challenges in the competitive landscape. Leqembi's fourth-quarter global in-market sales were approximately $87 million, with U.S. in-market sales of approximately $50 million. However, the level of education required for pioneering therapies like Leqembi and Skyclarys is significant, which may slow down their adoption and growth.

To mitigate the risks associated with the expected revenue decline, investors can consider the following strategies:

1. Diversify Portfolio: Investors can diversify their portfolio by allocating funds to other healthcare or biotechnology companies that are not heavily reliant on a single product or franchise.
2. Monitor Pipeline Progress: Biogen has a pipeline of potential new products that could offset the decline in MS revenue. Investors should closely monitor the progress of these pipeline candidates, as successful development and commercialization could lead to future growth.
3. Evaluate Company's Strategic Moves: Biogen has been making strategic moves, such as the acquisition of Reata Pharmaceuticals and the collaboration with Royalty Pharma, to diversify its revenue streams. Investors should assess the potential impact of these strategic moves on the company's future performance.
4. Assess Management's Ability to Execute: Investors should evaluate the management team's ability to execute on their strategic plans, including cost-cutting initiatives and pipeline development, to mitigate the risks associated with the expected revenue decline.



In conclusion, Biogen's expected revenue decline in 2025 highlights the challenges faced by the company in the competitive MS market and the need for investors to consider strategic moves to mitigate risks. By diversifying their portfolio, monitoring pipeline progress, evaluating strategic moves, and assessing management's ability to execute, investors can make informed decisions about their investments in Biogen and other biotechnology companies.